{
  "study_id": "DECIPHERA-PV-3",
  "study_name": "Sapablursen Phase 3",
  "sponsor": "Deciphera Life Sciences",
  "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Sapablursen in Adults with Phlebotomy-Dependent Polycythemia Vera",
  "phase": "3",
  "indication": "Polycythemia Vera",
  "therapeutic_area": "Hematology",
  "indication_level_quotes": "1540",
  "therapeutic_area_quotes": "11970",
  "population": {
    "age_range": "Adults 18+",
    "condition": "Phlebotomy-dependent Polycythemia Vera",
    "inclusion_highlights": [
      "Diagnosis of PV per WHO 2016 criteria",
      "Phlebotomy dependent (\u22653 in 28 weeks or \u22655 in 1 year)",
      "Hematocrit <45% prior to randomization",
      "ECOG performance status 0-2",
      "Stable CRT regimen or none"
    ]
  },
  "design": {
    "randomization": "Yes",
    "control": "Placebo-controlled",
    "blinding": "Double-blind",
    "arms": 2,
    "multicenter": true
  },
  "total_visits": 39,
  "total_weeks": 156,
  "visit_schedule_json": "sapablursen_pv_visit_schedule.json"
}